Session 1 Posters

Session 1 Posters (Sorted by Poster Number)

Link to abstract book
Link to Poster Session 2 – Thursday 15:00–17:00
Submission Id Poster number Primary Topic Presenting Title
6 P-001 Complement and infection (including COVID-19) Yi-Pin Lin The vector-pathogen anti-complement evolution dictates host skin immunomodulation for multimodal Lyme disease bacterial transmission
7 P-002 Complement and infection (including COVID-19) Katarzyna Kuska New roles of intracellular C3 in triggering immune responses
18 P-004 Complement and infection (including COVID-19) Tahsin Ahamed Khan Complement evasion strategies of Candida glabrata clinical isolates and antibody independent binding of C1q to C. glabrata
40 P-005 Complement and infection (including COVID-19) Eija Nissilae Complement activation and immune responses induced by Nuvaxovid and ChAdOx1 vaccines against Covid-19
88 P-006 Complement and infection (including COVID-19) Anthony Shadid MicroRNA sequencing of plasma exosomes reveals complement dysregulation in COVID-19
106 P-007 Complement and infection (including COVID-19) Kristian Riesbeck Molecular epidemiology and comparative virulence patterns of Acinetobacter baumannii isolates from war-related injuries in Ukraine
112 P-009 Complement and infection (including COVID-19) Lilith Heiland Evasion of Complement and Amyloid-Beta by the Neurotropic Pathogen Borrelia burgdorferi in Human 3D Cultures
114 P-010 Complement and infection (including COVID-19) Kristian Riesbeck Major outer membrane protein P5 of non-typeable Haemophilus influenzae interacts with human vitronectin and contributes to serum resistance
127 P-012 Complement and infection (including COVID-19) Peter Szachowicz Complement expression determines disease severity in mouse models of SARS-CoV-2 and influenza pneumonia
141 P-014 Complement and infection (including COVID-19) Panisadee Avirutnan Epitope-Dependent Complement Activation and ADCC by Anti-NS1 Antibodies in Targeting Infected Cells: Implications for Dengue Vaccine Design
157 P-016 Complement and infection (including COVID-19) JOHN JOHNSON Host Cell Origin Drives Divergent Complement Neutralization Mechanisms of Chandipura Virus
9 P-017 Complement assays and biomarkers Frank Beurskens Characterization of antibody Fc:Fc interactions by a VHH blocking technology
42 P-018 Complement assays and biomarkers Vandana Pradhan Deciphering the lectin pathway among Systemic Lupus Erythematosus (SLE) patients from Western India
47 P-019 Complement assays and biomarkers Nicole Meyer Complement Factor I Functional Assay for Assessing CFI Variants
56 P-020 Complement assays and biomarkers Naia Vad Stampe Development and Evaluation of Alternative Pathway Factor B Neoantigen Assay Using Novel Monoclonal Antibodies
60 P-021 Complement assays and biomarkers Bettina Eide Holm Isoform-Specific Detection and Quantification of Complement C4A via Novel mAbs
62 P-022 Complement assays and biomarkers Lewis M Watkins Profiling complement dysregulation in frontotemporal dementia using cerebrospinal fluid, plasma, and exosomes.
63 P-023 Complement assays and biomarkers Robert AJ Byrne Novel anti-clusterin monoclonals as tools for characterising clusterin expression in biofluids and tissues
65 P-024 Complement assays and biomarkers Gareth D. Fenn Development of a novel dual fluorescent ELISA (FELISA) for the simultaneous quantification of C3 and C3a in biological fluids.
66 P-025 Complement assays and biomarkers Vinira Wijesuriya Cerebrospinal fluid complement system biomarkers in Alzheimer’s disease.
84 P-026 Complement assays and biomarkers Bill Ho Reconstitution of a fully functional recombinant membrane attack complex for molecular biology studies
108 P-027 Complement assays and biomarkers Laura Nicholls C3 and C3a as Indicators of Complement Dysregulation in Tauopathies and FTLD-Associated Disorders.
129 P-028 Complement assays and biomarkers Samuel Butler A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
130 P-029 Complement assays and biomarkers Michael Schwenkert Advanced Assay Platform for Antibody Development: Precision Assays for ADCC, ADCP, and CDC
151 P-031 Complement assays and biomarkers Kirsten L Baillie Novel antibodies and assays to ascertain the role of C4 protein variants in Schizophrenia risk
28 P-033 Complement pathways, activation and regulation Joanne van Keulen Distinct sites of complement activation and regulation in the tumor microenvironment
29 P-034 Complement pathways, activation and regulation Cobey Donelson Integration of Structural Modeling and CADD Scores Improve Variant Classification for CFH SCRs 5-18
33 P-035 Complement pathways, activation and regulation Masashi Mizuno Comparison of complement activation products and eosinophils between bicarbonate-based and lactate-based peritoneal dialysis (PD) solutions in PD patients during introduction periods.
39 P-037 Complement pathways, activation and regulation Jean-Baptiste Reiser The Fc fragment of soluble IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement-dependent cytotoxicity
55 P-038 Complement pathways, activation and regulation Boglár Gál A Novel Immunoassay Platform to Study the Dynamics of the Alternative Pathway
59 P-039 Complement pathways, activation and regulation Tereza Alica Plchová Novel Quantitative ELISA Reveals Dynamics of Pro-Factor D Conversion During Alternative Complement Pathway Activation
61 P-040 Complement pathways, activation and regulation Michael Rückert High-dose radiotherapy modulates the expression and secretion of complement (regulatory) proteins by tumor cells
76 P-041 Complement pathways, activation and regulation Peter Zipfel The Four Functional Segments of Factor H:Role in Physiological Target Recognition and Contribution to Disease
93 P-043 Complement pathways, activation and regulation Joshua Dent Design and development of potent and selective C5aR2 agonists
94 P-044 Complement pathways, activation and regulation Marina Vygonskaya ROLE OF COMPLEMENT COMPONENTS 3A (C3A) AND 5A (C5A) IN THE ACUTE-TO-CHRONIC PAIN TRANSITION IN A MOUSE MODEL OF NEUROPATHIC PAIN.
123 P-045 Complement pathways, activation and regulation Linnea Lindelöf Ficolin-3 Recognizes Acylated and Carbamylated Lysine Residues and Activates Complement in a pH-Dependent Manner
125 P-046 Complement pathways, activation and regulation Roland Ebert Update on protein array screening of the ficolin-3 interactome
131 P-047 Complement pathways, activation and regulation Mihály Józsi The Tumor- and Apoptosis-Associated Annexin A2 is a New Ligand for FHL-1 and Factor H-Related Proteins – Annexin-Bound FHR-5 Enhances Alternative Pathway Activation
134 P-048 Complement pathways, activation and regulation Mihály Józsi The human complement factor H-related protein FHR-2 enhances complement activation on host and bacterial ligands
152 P-051 Complement pathways, activation and regulation Per H. Nilsson Complement C3 inhibition mitigates complement activation in clinical platelet concentrates without preventing platelet storage lesions
154 P-052 Complement pathways, activation and regulation Anas Abu-Humaidan Differential Complement Responses in Radiation- vs. Chemotherapy-Induced Senescence
155 P-053 Complement pathways, activation and regulation Steffen Thiel Something about the at least 50 different complexes of the initiating molecules of the lectin pathway and the polyreactivity of the pattern recognition molecules.
43 P-057 Complement structure and function Marie Jachmann The toxin CyaA from Bordetella pertussis as a potential modulator of Complement receptor 3 (CR3) function
50 P-058 Complement structure and function Rebekah S Cooke C5 inhibition by mAbs: There’s many ways to skin a cat!
53 P-059 Complement structure and function Sudha Mishra A conserved molecular mechanism orchestrates diverse ligand recognition at the complement anaphylatoxin receptor C3aR
75 P-060 Complement structure and function Jubayer Rahman A CD4+ T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 contraction and is perturbed in Th1-driven disease states
122 P-063 Complement structure and function Juliane Klehr Impact of the A09/A15 epitope on structural assembly and function of C1q in the light of Systemic Lupus Erythematosus
140 P-065 Complement structure and function David Eikrem Targeted binding and activation of native C3 without proteolytic cleavage induced by flip/flopped cell membranes
142 P-066 Complement structure and function Changhao Jia Structural basis of complement C3 recognition by both convertases
2 P-069 Complement therapeutics Sarah Hammadi Utilising induced pluripotent stem cells (iPSCs) to model the outer retina for complement gene therapy delivery